Description: Radiopharm Theranostics Limited engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas of high unmet medical needs. It develops RAD 204, a programmed death-ligand 1 (PD-L1) for the treatment of non-small cell lung cancer (NSCLC); RAD 202, a human epidermal growth factor receptor 2 (HER2) to treat breast cancer and other solid tumors; and RAD 301, a diagnostic radiopharmaceutical targeting avß6 integrin in pancreatic ductal adenocarcinoma patients. The company also develops RAD 302, an avß6-integrin targeting agent for the treatment of multiple cancer types; RAD 101 and RAD 102 for brain metastases; RAD 402 to treat advanced prostate cancer; and RV01 for multiple solid tumors. The company was incorporated in 2021 and is based in Carlton, Australia.
Home Page: www.radiopharmtheranostics.com
62 Lygon Street
Carlton,
VIC
3053
Australia
Phone:
61 3 9824 5254
Officers
| Name | Title |
|---|---|
| Mr. Paul Edward-Alexander Hopper A.S.i.A, B.A (UNSW), FAICD | Founder & Executive Chairman |
| Mr. Riccardo Canevari | MD, CEO & Director |
| Mr. Phillip Hains | CFO, Joint Company Secretary & Director |
| Dr. Thomas H. Tulip Ph.D. | Chief Business Officer |
| Dr. Dimitris Voliotis M.D. | Chief Medical Officer |
| Mr. Nathan Jong C.A. | Joint Company Secretary |
Exchange: PINK
Country: US : United States of America
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.0229 |
| Price-to-Sales TTM: | 5.9402 |
| IPO Date: | |
| Fiscal Year End: | June |
| Full Time Employees: | 0 |